A Novel cytarabine analog evokes synthetic lethality by targeting MK2 in p53-deficient cancer cells

Cabozantinib Eradicates Advanced Murine Prostate Cancer by Activating Antitumor Innate Immunity

(2017) Akash Patnaik et al.   Cancer Discovery

Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors

(2015) Christopher J. Lord et al.   Annual Review of Medicine

Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine

(2015) Claudia Fiorini et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

Cabozantinib in Chemotherapy-Pretreated Metastatic Castration-Resistant Prostate Cancer: Results of a Phase II Nonrandomized Expansion Study

(2014) Matthew R. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Advances in the development of nucleoside and nucleotide analogues for cancer and viral diseases

(2013) Lars Petter Jordheim et al.   NATURE REVIEWS DRUG DISCOVERY

A Reversible Gene-Targeting Strategy Identifies Synthetic Lethal Interactions between MK2 and p53 in the DNA Damage Response In Vivo

(2013) Sandra Morandell et al.   Cell Reports

Levels of Gemcitabine Transport and Metabolism Proteins Predict Survival Times of Patients Treated With Gemcitabine for Pancreatic Adenocarcinoma

(2012) Raphaël Maréchal et al.   GASTROENTEROLOGY

Discovery of Potent and Selective Inhibitors of Ataxia Telangiectasia Mutated and Rad3 Related (ATR) Protein Kinase as Potential Anticancer Agents

(2011) Jean-Damien Charrier et al.   JOURNAL OF MEDICINAL CHEMISTRY

Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth

(2011) F. M. Yakes et al.   MOLECULAR CANCER THERAPEUTICS

Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR

(2011) Philip M Reaper et al.   Nature Chemical Biology

Mitotic catastrophe: a mechanism for avoiding genomic instability

(2011) Ilio Vitale et al.   NATURE REVIEWS MOLECULAR CELL BIOLOGY

A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations

(2011) Luis I Toledo et al.   NATURE STRUCTURAL & MOLECULAR BIOLOGY

Inhibition of cell growth and potentiation of tumor necrosis factor-α (TNF-α)-induced apoptosis by a phenanthroindolizidine alkaloid antofine in human colon cancer cells

(2010) Hye-Young Min et al.   BIOCHEMICAL PHARMACOLOGY

The ribonucleotide reductase large subunit (RRM1) as a predictive factor in patients with cancer

(2010) Lars Petter Jordheim et al.   LANCET ONCOLOGY

DNA Damage Activates a Spatially Distinct Late Cytoplasmic Cell-Cycle Checkpoint Network Controlled by MK2-Mediated RNA Stabilization

(2010) H. Christian Reinhardt et al.   MOLECULAR CELL

Combined Src and Aromatase Inhibition Impairs Human Breast Cancer Growth In vivo and Bypass Pathways Are Activated in AZD0530-Resistant Tumors

(2009) Y. Chen et al.   CLINICAL CANCER RESEARCH

The combined status of ATM and p53 link tumor development with therapeutic response

(2009) H. Jiang et al.   GENES & DEVELOPMENT

Discovery of a New Template for Anticancer Agents: 2′-deoxy-2′-fluoro-4′-selenoarabinofuranosyl-cytosine (2′-F-4′-Seleno-ara-C)

(2009) Lak Shin Jeong et al.   JOURNAL OF MEDICINAL CHEMISTRY

First Synthesis of 4‘-Selenonucleosides Showing Unusual Southern Conformation

(2007) Lak Shin Jeong et al.   ORGANIC LETTERS